Recent Updates
Recently added Catalysts
BEAM Positive Sentiment

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Thursday, July 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Beam Therapeutics is set to present updated data from its Phase 1/2 trial of BEAM-302, targeting Alpha-1 Antitrypsin Deficiency (AATD). The presentation will occur at the European Respiratory Society (ERS) Congress in 2026. Additionally, the company will host an investor webcast to discuss the clinical data on September 8, 2026.
Price reaction · baseline $26.64 (2026-07-22 close) · hit pre-market · clean, no other BEAM news in the window
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Beam Therapeutics is advancing its BEAM-302 clinical trial.
  • The presentation at the ERS Congress highlights significant progress.
  • Investor webcast indicates transparency and engagement with stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
8.7%
average across 2 past catalysts
Cash runway
~52 mo
Minimal dilution risk
Lead asset
BEAM-302
Phase 1 · Alpha 1-Antitrypsin Deficiency

Full Press Release Details

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today

Frequently Asked Questions

What is BEAM-302?

BEAM-302 is a clinical trial by Beam Therapeutics targeting Alpha-1 Antitrypsin Deficiency.

When will the BEAM-302 data be presented?

The updated data from the BEAM-302 trial will be presented at the ERS Congress in 2026.

What is the purpose of the investor webcast?

The investor webcast will review the clinical data related to BEAM-302.

When is the investor webcast scheduled?

The investor webcast is scheduled for September 8, 2026, at 7:00 a.m. ET.

ShareAdd on Google
Tags: BEAM Viatris Investor Conferences Healthcare Beam Therapeutics BEAM-302 Alpha-1 Antitrypsin Deficiency ERS Congress clinical trial
Last updated: Jul 23, 2026

Biotech snapshot

Cash runway
$1153M liquidity · $22M/mo burn
~52 mo
Minimal dilution risk
Lead asset
BEAM-302Phase 1
Alpha 1-Antitrypsin Deficiency →

Catalyst track record

+52%
best trade around BEAM's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for BEAM.

See every catalyst's timing & PoA →